Researchers at the University of California, Davis have developed a unique topical treatment for chronic cutaneous wounds using selective serotonin reuptake inhibitors.
Chronic wounds represent a significant source of morbidity in the United States, and evidence suggests that inflammation contributes to wound chronicity. Targeting this inflammation in wound healing will help lead to targeted therapies that can increase patient quality of life and decrease healthcare costs. Effect on quality of life for patients with chronic wounds is equivalent to that of heart or kidney disease. Unfortunately, treatment options for chronic wounds are limited and at least 30% of the ulcers fail to heal within the first 20 weeks with currently available therapies. Furthermore, there is a high association of diabetic foot ulcers with amputation, highlighting the need for more effective therapies.
Researchers at the University of California, Davis have developed a topical preparation of selective serotonin reuptake inhibitors (SSRI) for the treatment of chronic cutaneous wounds. This method of delivery not only avoids unnecessary trauma to the skin but limits systemic effects. These researchers have shown that their unique topical SSRI formulation leads not only to improved skin cell migration over wounds but also decreased inflammation, resulting in better wound healing.
|United States Of America||Published Application||20190105260||04/11/2019||2016-658|
chronic wound, diabetic foot ulcer, diabetic wound, venous ulcer, stasis ulcer, pressure ulcer, pressure sores, selective serotonin reuptake inhibitor, SSRI